Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Is Pfizer Stock a Yield Trap?

BBIO : 46.34 (+0.78%)
NVS : 123.75 (+0.66%)
PFE : 25.75 (+0.74%)
BMY : 48.49 (+1.74%)
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

OWL : 19.61 (+0.87%)
BBIO : 46.34 (+0.78%)
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BBIO : 46.34 (+0.78%)
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis

MCO : 506.02 (+0.76%)
PLD : 108.41 (+1.90%)
SPGI : 530.12 (+0.26%)
BBIO : 46.34 (+0.78%)
FDX : 238.75 (+0.95%)
HD : 373.74 (+0.73%)
PFE : 25.75 (+0.74%)
AMZN : 222.12 (-0.19%)
BMY : 48.49 (+1.74%)
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

BBIO : 46.34 (+0.78%)
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

BBIO : 46.34 (+0.78%)
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BBIO : 46.34 (+0.78%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO : 46.34 (+0.78%)
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BBIO : 46.34 (+0.78%)
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BBIO : 46.34 (+0.78%)

Barchart Exclusives

Intel Is Kicking Off a Major Layoffs Push. What Do the Job Cuts Mean for INTC Stock?
Intel’s sweeping layoffs highlight a dramatic push to cut costs and streamline operations as it battles to reclaim lost market share. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar